Systematic Review and Meta-Analysis of the Significance of Heterogeneous Vancomycin-IntermediateStaphylococcus aureusIsolates
出版年份 2010 全文链接
标题
Systematic Review and Meta-Analysis of the Significance of Heterogeneous Vancomycin-IntermediateStaphylococcus aureusIsolates
作者
关键词
-
出版物
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 55, Issue 1, Pages 405-410
出版商
American Society for Microbiology
发表日期
2010-11-16
DOI
10.1128/aac.01133-10
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Reduced Vancomycin Susceptibility in Staphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications
- (2010) B. P. Howden et al. CLINICAL MICROBIOLOGY REVIEWS
- Staphylococcus aureus with reduced glycopeptide susceptibility in Liverpool, UK
- (2010) A. Kirby et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Detection and Characterization of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates in Canada: Results from the Canadian Nosocomial Infection Surveillance Program, 1995-2006
- (2009) H. J. Adam et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Prevalence and Characterization of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates from 14 Cities in China
- (2009) W. Sun et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Prospective Comparison of the Clinical Impacts of Heterogeneous Vancomycin-Intermediate Methicillin-Resistant Staphylococcus aureus (MRSA) and Vancomycin-Susceptible MRSA
- (2009) K. C. Horne et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore
- (2009) R. K. C. Fong et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals
- (2009) H. S. Sader et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- The First Vancomycin-Intermediate Staphylococcus aureus Strains Isolated from Patients in Thailand
- (2009) A. Lulitanond et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Vancomycin MIC plus Heteroresistance and Outcome of Methicillin-Resistant Staphylococcus aureus Bacteremia: Trends over 11 Years
- (2009) A. C. Musta et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Heterogeneous Vancomycin‐Intermediate Susceptibility Phenotype in Bloodstream Methicillin‐ResistantStaphylococcus aureusIsolates from an International Cohort of Patients with Infective Endocarditis: Prevalence, Genotype, and Clinical Significance
- (2009) In‐Gyu Bae et al. JOURNAL OF INFECTIOUS DISEASES
- Clinical Features of Heteroresistant Vancomycin-IntermediateStaphylococcus aureusBacteremia versus Those of Methicillin-ResistantS. aureusBacteremia
- (2009) Yasmin Maor et al. JOURNAL OF INFECTIOUS DISEASES
- Incidence and Characteristics of Vancomycin Nonsusceptible Strains of Methicillin-Resistant Staphylococcus aureus at Hershey Medical Center
- (2008) K. Kosowska-Shick et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia
- (2008) Benjamin P Howden et al. BMC MICROBIOLOGY
- Characterization of Vancomycin-Heteroresistant Staphylococcus aureus from the Metropolitan Area of Detroit, Michigan, over a 22-Year Period (1986 to 2007)
- (2008) M. J. Rybak et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Influence of Vancomycin Minimum Inhibitory Concentration on the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia
- (2007) A. Soriano et al. CLINICAL INFECTIOUS DISEASES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started